A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single-ascending Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-06818883 Following Single Intravenous Administration In Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single-ascending Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-06818883 Following Single Intravenous Administration In Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs PF 6818883 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Jul 2017 Status changed from suspended to discontinued.
    • 24 Apr 2017 Status changed from recruiting to suspended.
    • 02 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top